villarabbit.blogg.se - Kullo iftikhar mayo clinic

The research team is also studying the association of arterial stiffness on measures of left ventricular function including longitudinal strain and diastolic function. The laboratory is investigating the clinical utility of measures of arterial stiffness such as aortic pulse wave velocity and characteristic impedance.

Arterial stiffness and ventricular arterial interactions.

Kullo's team studies the connections between novel protein markers and measurable traits of vascular disease, such as coronary artery calcium, cerebral leukoaraiosis, albuminuria and ankle-brachial index, with the goal of identifying new proteomic markers for vascular disease.

Proteomic markers for vascular disease.

Kullo and collaborators are working with the Electronic Medical Records and Genomics (eMERGE) Network to develop better ways to use EHR-linked biorepositories for large-scale genomic research. Another project is investigating the clinical utility of a genetic risk score composed of susceptibility variants for abdominal aortic aneurysm.

Kullo's laboratory conducts clinical trials in genomic medicine, such as the recently concluded Myocardioal Infarction Genes (MI-GENES) study, which assessed the effect on LDL cholesterol of disclosing a genetic risk score for coronary heart disease based on 28 susceptibility variants. Implementing genomic medicine in the EHR.Kullo's laboratory is engaged in several projects related to FH, including the use of electronic phenotyping for rapid ascertainment of FH from electronic health records (EHRs), use of EHR-based strategies to improve outcomes in patients with FH, assigning pathogenicity to variants identified from sequencing of FH-related genes and investigating the pleiotropic effects of FH-related genes. Kullo's lab uses family history studies, linkage studies, candidate gene association studies, genome-wide association studies and genome sequencing to study the genetic basis of atherosclerosis. Genetics of arterial plaques (atherosclerosis).These include genetic markers, circulating biomarkers, and noninvasive tests of arterial function and structure.

Kullo is investigating the use of new methodologies in refining cardiovascular risk stratification. Through his Atherosclerosis and Lipid Genomics Laboratory, Dr. Kullo, M.D., is in biomarkers of cardiovascular risk. The main research interest of Iftikhar J. Genomics is transforming biomedical research and I’m excited to have the opportunity to advise on the discovery and implementation aspects of genomic medicine to improve outcomes for our patients,” Dr Kullo has said after his appointment to the National Advisory Council on Human Genome Research. “I am honoured to serve on the National Advisory Council on Human Genome Research. Besides, the NACHGR performs second-level peer review for grant applications and determines the programme priorities for NHGRI and the goals for the government’s efforts in the International Human Genome Project (HGP). The NACHGR advises the US Department of Health and Human Services (DHHS), the National Institutes of Health (NIH), and the National Human Genome Research Institute (NHGRI), on genetics, genomic research, and training and programs related to the human genome initiative. Dr Iftikhar will be part of the council till September 30, 2024. The orders were issued by Xavier Becerra, Joe Biden’s Secretary of Health and Human Services (DHHS). Srinagar born and Government Medical College (GMC Srinagar) MBBS pass out and now top Kashmiri American cardiologist Dr Iftikhar J Kullo has been nominated to the National Advisory Council on Human Genome Research (NACHGR) that the US National Institutes of Health (NIH) runs.